Effects of Molecular Iodine/Chemotherapy in the Immune Component of Breast Cancer Tumoral Microenvironment

Cuenca-Micó, Olga; Delgado‐González, Evangelina; Anguiano, Brenda; Vaca-Paniagua, Felipe; Medina-Rivera, Alejandra; Rodríguez-Dorantes, Mauricio; Aceves, Carmen

doi:10.3390/biom11101501

Cited by 7 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6-iodolactone, a product of molecular iodine transformation, is known to activate apoptosis [14]. Another mechanism for iodine's antitumor activity may involve its effect on activating the immune response via the Th1 pathway [15]. Additionally, iodine solutions used in cancer radiotherapy have anti-inflammatory effects on mucous membranes [16].…”

Section: Resultsmentioning

confidence: 99%

ChemoProtective effects of new iodine coordinated compound in benzo[a]pyrene- induced lung cancer in BALB/c mice

Abekova,

Islamov

2024

BIO Web Conf.

View full text Add to dashboard Cite

Iodine preparations are widely used in medicine as antiseptic agents. One of the new directions for the use of iodine is the prevention and therapy of certain tumor diseases, particularly breast cancer. The main mechanism of action is the induction of apoptosis. Iodine also has anti-inflammatory activity and affects the polarization of Th1/Th2 lymphocytes and M1/M2 macrophages. The newly developed iodine complex KC-144 includes both dextrin and polypeptides. In this case, lithium enhances the polarization of triiodide. We studied the acute toxicity and prophylactic activity on a model of benz(a)pyrene-induced (BaP) tumor in BALB/c mice. The average lethal dose (LD50) of KC-144 when administered orally was more than 2500 mg/kg, classifying KC-144 as a low-toxicity substance. Intraperitoneal administration of benz(a)pyrene at a dose of 100 mg/kg for two weeks induces tumor development in mice. Oral administration of KC-144 at doses of 2.5 and 25 mg/kg for one week and throughout the entire treatment period increases the lifespan of BaP-induced mice.

show abstract

Section: Resultsmentioning

confidence: 99%

ChemoProtective effects of new iodine coordinated compound in benzo[a]pyrene- induced lung cancer in BALB/c mice

Abekova,

Islamov

2024

BIO Web Conf.

View full text Add to dashboard Cite

show abstract

“…The most common CD molecules mentioned in the publications included in this review of breast and pancreatic cancers were CD4 and CD8, in the context of treatment ( 53 , 55 , 91 ); while others such as CD19 and CD16 were also assessed in several studies, both for treatment as well ( 85 ). In addition, CA15-3, Type 1 T helper cells (Th1), C-reactive protein (CRP), and VEGF were also used in more than three studies for breast cancer for the purpose of diagnosis and treatment ( 30 , 33 , 51 , 54 , 59 , 61 , 63 , 66 , 78 , 79 ). Other biomarkers like insulin, C-C motif chemokine ligand 2 (CCL2), transforming growth factor β 1(TGF-β1), and Treg-like molecule (Treg: Regulatory T cells) were also discussed in some of our reviewed publications, regarding their relevance primarily to breast cancer treatment ( 75 , 76 , 80 , 83 , 84 , 88 , 90 ).…”

Section: Resultsmentioning

confidence: 99%

Clinical trial-identified inflammatory biomarkers in breast and pancreatic cancers

et al. 2023

View full text Add to dashboard Cite

Breast cancer and pancreatic cancer are two common cancer types characterized by high prevalence and high mortality rates, respectively. However, breast cancer has been more well-studied than pancreatic cancer. This narrative review curated inflammation-associated biomarkers from clinical studies that were systematically selected for both breast and pancreatic cancers and discusses some of the common and unique elements between the two endocrine-regulated malignant diseases. Finding common ground between the two cancer types and specifically analyzing breast cancer study results, we hoped to explore potential feasible methods and biomarkers that may be useful also in diagnosing and treating pancreatic cancer. A PubMed MEDLINE search was used to identify articles that were published between 2015-2022 of different kinds of clinical trials that measured immune-modulatory biomarkers and biomarker changes of inflammation defined in diagnosis and treatment of breast cancer and pancreatic cancer patients. A total of 105 papers (pancreatic cancer 23, breast cancer 82) were input into Covidence for the title and abstract screening. The final number of articles included in this review was 73 (pancreatic cancer 19, breast cancer 54). The results showed some of the frequently cited inflammatory biomarkers for breast and pancreatic cancers included IL-6, IL-8, CCL2, CD8+ T cells and VEGF. Regarding unique markers, CA15-3 and TNF-alpha were two of several breast cancer-specific, and CA19 and IL-18 were pancreatic cancer-specific. Moreover, we discussed leptin and MMPs as emerging biomarker targets with potential use for managing pancreatic cancer based on breast cancer studies in the future, based on inflammatory mechanisms. Overall, the similarity in how both types of cancers respond to or result in further disruptive inflammatory signaling, and that point to a list of markers that have been shown useful in diagnosis and/or treatment method response or efficacy in managing breast cancer could potentially provide insights into developing the same or more useful diagnostic and treatment measurement inflammatory biomarkers for pancreatic cancer. More research is needed to investigate the relationship and associated inflammatory markers between the similar immune-associated biological mechanisms that contribute to breast and pancreatic cancer etiology, drive disease progression or that impact treatment response and reflect survival outcomes.

show abstract

“…11A ). It was reported that patients with high expression of TGFB1 have immunosuppressive microenvironment and are resistant to ICI treatment [ 8 - 11 ]. We found that TGFB1 expression was lower in high cuproptosis score group (Fig.…”

Section: Resultsmentioning

confidence: 99%

“…We found that common immune checkpoints, such as PDCD1, LAG3, CTLA4, CD274 and TIGIT were highly expressed in high cuproptosis score group. It was reported that patients with high expression of TGFB1 have immunosuppressive microenvironment and are resistant to ICI treatment [ 8 - 10 ]. We found that TGFB1 expression was lower in high cuproptosis score group.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of Cuproptosis Genes and Identification of Cuproptosis Subtypes in Breast Cancer

Dong

et al. 2023

CCHTS

View full text Add to dashboard Cite

Background: Copper-induced death (cuproptosis) is copper-dependent regulated cell death, which is different from known death mechanisms and is dependent on mitochondrial respiration. However, its effect on breast cancer (BRCA) is unclear. Objective: The objective of this study is to explore the important clinical significance of cuproptosis genes and to provide a new idea for guiding the personalized immunotherapy strategy of BRCA patients. Materials and Method: We collected cuproptosis genes from published work. The gene alteration, differential expression, and prognostic value of cuproptosis genes were explored in BRCA based on TCGA database. We identified two subtypes (clusters A and B) by performing unsupervised clustering. The difference between two clusters was deeply explored, including clinical features, differential expressed genes (DEGs), pathways, and immune cell infiltration. Based on the DEGs between two clusters, a cuproptosis score was constructed and its predictive capability for overall survival of BRCA patients was validated. Results and Discussion: Patients with high cuproptosis score have worse survival status, with an increased infiltration level of most immune cells. Further analysis suggested that BRCA patients with high cuproptosis score may be sensitive to immune checkpoint inhibitor (ICI) treatment. Conclusion: Our findings may improve our understanding of cuproptosis in BRCA and may distinguish patients suitable for ICI treatment. conclusion: Our findings may improve our understanding of cuproptosis in BRCA and may distinguish patients suitable for ICI treatment.

show abstract

Effects of Molecular Iodine/Chemotherapy in the Immune Component of Breast Cancer Tumoral Microenvironment

Cited by 7 publications

References 42 publications

ChemoProtective effects of new iodine coordinated compound in benzo[a]pyrene- induced lung cancer in BALB/c mice

ChemoProtective effects of new iodine coordinated compound in benzo[a]pyrene- induced lung cancer in BALB/c mice

Clinical trial-identified inflammatory biomarkers in breast and pancreatic cancers

Comprehensive Analysis of Cuproptosis Genes and Identification of Cuproptosis Subtypes in Breast Cancer

Contact Info

Product

Resources

About